Literature DB >> 29356944

A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I.

Satoshi Takasaki1, Akira Matsunaga2, Kensuke Joh3, Takao Saito4.   

Abstract

Lipoprotein glomerulopathy (LPG) is a rare inherited disease characterized by histopathological features of lipoprotein thrombi in dilated glomerular capillaries and type III like hyperlipoproteinemia with heterozygous mutation of the apolipoprotein (apo) E gene. We herein present the case of a 50-year-old woman with LPG complicated by neurofibromatosis type 1 (NF1). To the best of our knowledge, this is the first report of a case of LPG complicated by NF1. On the other hand, she had not only a heterozygous apoE-Sendai mutation, which is one of the most frequent apoE variants in LPG patients, but also a rare isoform of ApoE5 (Glu3Lys). Although apoE mutation has been recognized as having a principal role in the pathogenesis of LPG, some other factors are assumed to be present in the pathogenesis of LPG, because many asymptomatic carriers of apoE variants are recognized. The coexistence of NF1 or apoE5 (Glu3Lys) allele might play a role as an additional factor in the development of LPG.

Entities:  

Keywords:  ApoE-Sendai; ApoE5; Lipoprotein glomerulopathy; Neurofibromatosis type I

Year:  2018        PMID: 29356944      PMCID: PMC5886940          DOI: 10.1007/s13730-018-0309-2

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  18 in total

1.  Two apolipoprotein E5 variants illustrate the importance of the position of additional positive charge on receptor-binding activity.

Authors:  M R Wardell; S C Rall; E J Schaefer; J P Kane; K H Weisgraber
Journal:  J Lipid Res       Date:  1991-03       Impact factor: 5.922

2.  Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.

Authors:  S Oikawa; A Matsunaga; T Saito; H Sato; T Seki; K Hoshi; K Hayasaka; H Kotake; H Midorikawa; A Sekikawa; S Hara; K Abe; T Toyota; H Jingami; H Nakamura; J Sasaki
Journal:  J Am Soc Nephrol       Date:  1997-05       Impact factor: 10.121

3.  Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.

Authors:  Markus Gödel; Björn Hartleben; Nadja Herbach; Shuya Liu; Stefan Zschiedrich; Shun Lu; Andrea Debreczeni-Mór; Maja T Lindenmeyer; Maria-Pia Rastaldi; Götz Hartleben; Thorsten Wiech; Alessia Fornoni; Robert G Nelson; Matthias Kretzler; Rüdiger Wanke; Hermann Pavenstädt; Dontscho Kerjaschki; Clemens D Cohen; Michael N Hall; Markus A Rüegg; Ken Inoki; Gerd Walz; Tobias B Huber
Journal:  J Clin Invest       Date:  2011-05-23       Impact factor: 14.808

4.  A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.

Authors:  A Matsunaga; J Sasaki; T Komatsu; K Kanatsu; E Tsuji; K Moriyama; T Koga; K Arakawa; S Oikawa; T Saito; T Kita; T Doi
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

5.  Atypical hematologic and renal manifestations in neurofibromatosis type I: coincidence or pathophysiological link?

Authors:  Julien Van-Gils; Jérôme Harambat; Charlotte Jubert; Dominique Vidaud; Brigitte Llanas; Yves Perel; Didier Lacombe; Cyril Goizet
Journal:  Eur J Med Genet       Date:  2014-09-16       Impact factor: 2.708

6.  Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney.

Authors:  T Miyata; S Sugiyama; M Nangaku; D Suzuki; K Uragami; R Inagi; H Sakai; K Kurokawa
Journal:  J Am Soc Nephrol       Date:  1999-07       Impact factor: 10.121

7.  Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms.

Authors:  J M Ordovas; L Litwack-Klein; P W Wilson; M M Schaefer; E J Schaefer
Journal:  J Lipid Res       Date:  1987-04       Impact factor: 5.922

8.  Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities.

Authors:  Kenji Ito; Hitoshi Nakashima; Maho Watanabe; Atsunori Ishimura; Yoshito Miyahara; Yasuhiro Abe; Tetsuhiko Yasuno; Masakazu Ifuku; Yoshie Sasatomi; Takao Saito
Journal:  Nephrol Dial Transplant       Date:  2012-08-03       Impact factor: 5.992

9.  Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia.

Authors:  T Saito; H Sato; K Kudo; S Oikawa; T Shibata; Y Hara; K Yoshinaga; H Sakaguchi
Journal:  Am J Kidney Dis       Date:  1989-02       Impact factor: 8.860

10.  Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: a case report and proposed molecular pathways.

Authors:  Farsad Afshinnia; Virginia Vega-Warner; Paul Killen
Journal:  Clin Kidney J       Date:  2013-04
View more
  3 in total

Review 1.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

2.  Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys).

Authors:  Masaru Sasaki; Tetsuhiko Yasuno; Kenji Ito; Akira Matsunaga; Satoshi Hisano; Yasuhiro Abe; Katsuhisa Miyake; Kosuke Masutani; Hitoshi Nakashima; Takao Saito
Journal:  CEN Case Rep       Date:  2018-05-08

3.  A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.

Authors:  Runxiu Wang; Chengbo Zhao; Wen Chen; Zhiping Liu; Fuhua Xie
Journal:  J Med Case Rep       Date:  2022-02-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.